TRIPS-plus rights

TRIPS-plus rights refer to intellectual property (IP) protection standards that go beyond the minimum requirements set by the World Trade Organization's (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). These higher standards are typically established through Free Trade Agreements (FTAs) or Bilateral Investment Treaties. While the TRIPS Agreement provides a baseline, TRIPS-plus provisions often include longer patent terms, data exclusivity for pharmaceutical test data, patent linkage, and stricter enforcement measures. In enterprise risk management, TRIPS-plus is a critical external regulatory risk. It directly impacts a company's freedom to operate, R&D strategy, and litigation exposure, particularly for IP-reliant industries like pharmaceuticals, biotech, and technology.

Enterprises can integrate TRIPS-plus considerations into their risk management framework through three key steps. First, **Regulatory Monitoring and Gap Analysis**: Systematically track FTAs in key markets to identify TRIPS-plus provisions and compare them against the company's current IP practices to find compliance gaps. Second, **Risk Assessment and Strategy Adjustment**: Quantify potential risks, such as litigation costs or market access delays, and adjust R&D and market entry strategies accordingly. For instance, a generic drug maker might delay launch in a market with extended data exclusivity. Third, **Internal Control Integration**: Update internal policies and supplier contracts to reflect these stricter standards. Measurable outcomes include achieving a 100% IP compliance rate in new markets and reducing IP-related legal disputes.

Taiwanese enterprises face three primary challenges with TRIPS-plus rights. First, **High Compliance Costs and Complexity**: Navigating the diverse and stringent standards across different FTAs requires significant legal resources, which is a burden for SMEs. Second, **Reduced Freedom to Operate**: Stricter rules on patent linkage and data exclusivity can delay the market entry of generic drugs and biosimilars, impacting Taiwan's competitive biotech sector. Third, **Supply Chain Vulnerabilities**: Companies must ensure their entire global supply chain adheres to the highest applicable TRIPS-plus standard, creating complex due diligence needs. Mitigation strategies include leveraging government consulting services, focusing R&D on novel innovations, and implementing robust supplier IP audit programs.

Winners Consulting specializes in TRIPS-plus rights for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact